European Association of Urology Congress (EAU) 2026 Annual Meeting
EAU 2026 Prostate Cancer
- EAU 2026: A Phase II, Randomized, Controlled Trial of Best Systemic Therapy versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer
- EAU 2026: Discussant: Best Systemic Therapy versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer
- EAU 2026: Discussant - PRIMARY2 – Impact of 68Ga-PSMA-11 PET/CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Non-Suspicious Findings on mpMR
- EAU 2026: PRIMARY2 – Impact of 68Ga-PSMA-11 PET/CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Non-Suspicious Findings on mpMRI: A Multi-Center, Phase III, Randomized Trial
- EAU 2026: What Do You Need for Decision-making in mHSPC in 2026?
EAU 2026 Bladder Cancer
- EAU 2026: Discussant: The EV-304 Paradigm Shift
- EAU 2026: Neoadjuvant and Adjuvant Enfortumab Vedotin + Pembrolizumab for Patients with Muscle Invasive Bladder Cancer Who Are Eligible for Cisplatin: Pathological and Surgical Outcomes in KEYNOTE-B15
- EAU 2026: TMT for MIBC: Radiation, Responsibility, and Recurrences -- Who Manages the Fallout, and How? Debater 2: Toxicity Happens but Is Manageable -- Radiation Oncologists Can and Should Take Responsibility
- EAU 2026: TMT for MIBC: Radiation, Responsibility, and Recurrences -- Who Manages the Fallout, and How? Debater 1: Radiation Toxicity Is Real and Its Urologists Who Manage the Consequences
- EAU 2026: Peri-procedural Prophylactic Antibiotic Use with Gemcitabine Intravesical System Monotherapy: Analysis of Data from SunRISe-1
EAU 2026 Kidney Cancer
- EAU 2026: Adjuvant Pembrolizumab + Belzutifan for Clear Cell RCC: Primary and Exploratory Efficacy Outcomes from the Phase 3 LITESPARK-022 Study
- EAU 2026: Society of Urologic Oncology (SUO) Lecture: Rare Renal Tumors: What Should the General Urologist Know?
- EAU 2026: [89Zr]Zr-girentuximab PET/CT in the Non-invasive Characterization of Indeterminate Renal Lesions: Initial Real-world Clinical Experience
- EAU 2026: Impact of 89Zr-girentuximab PET Versus Conventional Imaging on Clinical Decision-making in Patients with Indeterminate Renal Masses (ZIRCON-X)
- EAU 2026: First-in-human Phase I Evaluation of [⁶⁸Ga]Ga-OncoCAIX PET/CT in Clear Cell Renal Cell Carcinoma: Preliminary Diagnostic Performance, Safety and Biodistribution
EAU 2026 Penile, Urethral, Testicular, and Adrenal Cancers
EAU 2026 Upper Tract Urothelial Carcinoma
- EAU 2026: International Delphi Consensus on UTUC Management: The IMPACT UTUC Project
- EAU 2026: DISTINCT-I: Perioperative Disitamab Vedotin and Tislelizumab Followed by Nephron-Sparing Surgery in High-Risk Upper Tract Urothelial Carcinoma: A Phase 2 Trial
- EAU 2026: Preliminary Results of a Phase II Study to Evaluate the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in Combination with Radiotherapy for Adjuvant Therapy in Upper Tract Urothelial Carcinoma
- EAU 2026: Efficacy and Safety of Disitamab Vedotin Combined with Tislelizumab as Adjuvant Therapy After Radical Surgery for Patients with HER2-Expression UTUC: A Prospective, Controlled, Phase II Study
- EAU 2026: Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced UTUC: CURATE-UTUC – A Multicenter Prospective Longitudinal Cohort Study
EAU 2026 Press Releases
- Co-PSMA Data Presented at EAU Annual Congress 2026 with Manuscript Accepted for Publication in the European Urology Journal
- Photocure: Trials in Progress Presented at the European Association of Urology (EAU) 2026 Congress Aim to Enable a More Personalized Bladder Cancer Care Pathway
- Timely Scan Could save Lives of A&E Patients with Blood in Urine